Cardiac Guidance vs EchoGo Amyloidosis
Similar category, different focus. These tools serve overlapping but distinct needs.
Comparability 65/100
Comparability is an AI-graded 0–100 score of how directly these two tools compete — higher means a more apples-to-apples comparison.
AI Verdict
Tool A focuses on empowering healthcare professionals to acquire and initially interpret diagnostic-quality cardiac ultrasound images at the point of care, providing real-time guidance and automated basic measurements. Tool B, conversely, is a specialized cloud-based screening tool designed to analyze existing echocardiogram video clips specifically for the early detection of cardiac amyloidosis. While both are FDA-cleared AI tools for cardiology utilizing echocardiography, they address different stages of the diagnostic workflow and serve distinct purposes.
Reviewed by Pouyan Golshani, MD — Interventional Radiologist
Frequently Asked Questions
Cardiac Guidance (Tool A) is an AI tool that helps healthcare professionals acquire and interpret diagnostic-quality cardiac ultrasound images at the point of care, including automated left ventricular ejection fraction (EF) calculation. EchoGo Amyloidosis (Tool B) is an AI-powered screening tool designed to analyze echocardiogram video clips to aid in the early detection of cardiac amyloidosis.
Cardiac Guidance (Tool A) provides real-time AI guidance for cardiac ultrasound image acquisition, offering turn-by-turn on-screen probe movement instructions and auto-capture of diagnostic-quality images. EchoGo Amyloidosis (Tool B) analyzes pre-recorded echocardiogram video clips to identify suspected cardiac amyloidosis.
Cardiac Guidance (Tool A) offers automated quality assessment with a 'Quality Meter,' auto-capture of diagnostic-quality images and video clips, and automated left ventricular ejection fraction (EF) calculation. EchoGo Amyloidosis (Tool B) provides a diagnostic output of 'suggestive' or 'not suggestive' of cardiac amyloidosis, based on its analysis of echocardiographic markers like ventricular volume, cardiac function, and myocardial movement.
For Cardiac Guidance (Tool A), new technology add-on payments (NTAP) have been approved by CMS for Medicare patients receiving inpatient care, with cases eligible for NTAP having a newly created ICD-10 procedure code. For EchoGo Amyloidosis (Tool B), specific reimbursement codes are available: NTAP Code ICD-10 XXE2X19 for inpatient analysis ($1,000, Medicare-covered) and HCPCS Code C9786 (Clinical APC Code 574) for outpatient analysis ($285, covered by Medicare and select commercial insurers).
Cardiac Guidance (Tool A) is designed for use by non-expert ultrasound users, empowering healthcare providers without prior ultrasound experience to acquire diagnostic-quality cardiac ultrasound images with real-time AI guidance. EchoGo Amyloidosis (Tool B) analyzes existing echocardiogram video clips to aid interpreting physicians in screening for cardiac amyloidosis.